Cutler Group LP Rhythm Pharmaceuticals, Inc. Transaction History

Cutler Group LP

$307 Million
Q1 2024

A detailed history of Cutler Group LP transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Cutler Group LP holds 1,100 shares of RYTM stock, worth $56,485. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,100

Previous 500 120.0%

Holding current value

$56,485

Previous $22,000 113.64%

% of portfolio

0.02%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	BUY	$39.12 - $52.44 $23,472 - $31,464	600 Added 120.0%	1,100 $47,000
Q4 2023 Jan 18, 2024	BUY	$21.39 - $49.64 $10,695 - $24,820	500 New	500 $22,000
Q1 2023 May 01, 2023	BUY	$16.88 - $34.24 $1,688 - $3,424	100 New	100 $1,000
Q3 2022 Oct 25, 2022	SELL	$4.3 - $30.85 $1,444 - $10,365	-336 Reduced 25.15%	1,000 $24,000
Q2 2022 Aug 04, 2022	SELL	$3.12 - $12.25 $1,560 - $6,125	-500 Reduced 27.23%	1,336 $5,000
Q1 2022 Apr 14, 2022	BUY	$6.13 - $12.24 $11,254 - $22,472	1,836 New	1,836 $21,000
Q3 2021 Oct 26, 2021	SELL	$11.68 - $20.72 $86,642 - $153,700	-7,418 Closed	0 $0
Q2 2021 Jul 19, 2021	SELL	$18.52 - $22.55 $14,519 - $17,679	-784 Reduced 9.56%	7,418 $145,000
Q1 2021 Apr 26, 2021	BUY	$20.25 - $39.49 $70,915 - $138,293	3,502 Added 74.51%	8,202 $174,000
Q4 2020 Jan 21, 2021	SELL	$21.17 - $32.61 $14,819 - $22,827	-700 Reduced 12.96%	4,700 $139,000
Q3 2020 Oct 27, 2020	BUY	$18.13 - $30.61 $81,585 - $137,745	4,500 Added 500.0%	5,400 $117,000
Q2 2020 Jul 22, 2020	BUY	$14.41 - $25.35 $11,528 - $20,280	800 Added 800.0%	900 $20,000
Q4 2019 Feb 06, 2020	SELL	$19.53 - $25.5 $1,953 - $2,550	-100 Reduced 50.0%	100 $2,000
Q2 2019 Aug 09, 2019	BUY	$21.11 - $28.48 $4,222 - $5,696	200 New	200 $4,000

Others Institutions Holding RYTM

# of Institutions

178

Shares Held

69.1M

Call Options Held

467K

Put Options Held

224K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $2.86B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account